Rate of Progression in EYS Related Retinal Degeneration

Exclusion Criteria

• •1. Mutations in genes that cause autosomal dominant retinitis pigmentosa (ADRP), X-linked retinitis pigmentosa (RP), or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than EYS
• •2. Expected to enter experimental treatment trial at any time during this study
• •3. History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy (including hydroxychloroquine, chloroquine, thioridazine, and deferoxamine)
• •1. Current vitreous hemorrhage
• •2. Current or any history of rhegmatogenous retinal detachment
• •3. Current or any history of (e.g., prior to cataract or refractive surgery) spherical equivalent of the refractive error worse than -8 Diopters of myopia
• •4. History of intraocular surgery (e.g., cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within the last 3 months
• •5. Current or any history of confirmed diagnosis of glaucoma (e.g., based on glaucomatous VF changes or nerve changes, or history of glaucoma filtering surgery)
• •6. Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy
• •7. History or current evidence of ocular disease that, in the opinion of the investigator, may confound assessment of visual function
• •8. History or evidence of active treatment for retinitis pigmentosa that could affect the progression of retinal degeneration, including:
• •1. Any use of ocular stem cell or gene therapy
• •2. Any treatment with ocriplasmin
• •3. Treatment with an ophthalmic oligonucleotide within the last 9 months (last treatment date is less than 9 months prior to Screening Visit date)
• •4. Treatment with any other product within five times the expected half-life of the product (time from last treatment date to Screening Visit date is at least 5 times the half-life of the given product)